This article was published free of charge. Only PREMIUM Articles are (Google AdSense™) 3rd party Ads-Free!
Bio3 Research Granted by the Australian PO a Patent in the Field of HMGB1
NewswireToday - /newswire/ -
Milano, Italy, 03/15/2007 - Italy, has been granted by the Australian Patent Office a patent in the field of cardiovascular diseases related to HMGB1 over-expression and for the use of HMGB1 protein in connective tissue regeneration.
Bio3 Research S.r.l. announced today that the Australian Patent Office has granted the company the patent in the HMGB1 (High Mobility Group Box 1 protein) field which entitles the use of antagonist molecules (Mabs and their fragments, Small Molecules inhibitors and antagonist molecules having sequence homology with HMG Box) that can bind the functional HMG Box binding domain of the receptor RAGE for the preparation of therapeutic agents for the treatment of vascular diseases, such as Atherosclerosis and Restenosis.
Furthermore, the granted patent entitles Bio3 Research to utilize HMGB1 as such and its fragments for the preparation of therapeutic agents which facilitate and/or induce Connective Tissue Regeneration.
Mr. Francesco Paolo Pilato, CEO Bio3 Research S.r.l., said: “We are very pleased for the Australian PO decision to grant the company said patent, which comes on the top of the already granted patent in Italy. Said patent entitles the company or licensed third parties the use of HMGB1 antagonists to treat cardiovascular disorders and to develop drugs based on HMGB1 as such and its fragments in the regeneration of damaged tissues. Remarkable scientific contribution has come from the studies conducted by Prof. Marco E. Bianchi (Inventor) an Associate Scientist of Bio3 Research. We strongly believe that the Pharmaceutical environment will soon consider HMGB1 as an innovative biological target for the development of drugs to prevent atherosclerotic plaque progression and restenosis after angioplasty. We are also very keen to develop treatments based on the use of HMGB1 as such, to regenerate damaged connective tissues. Preliminary animal data in cartilage repair are encouraging Bio3 Research to proceed further, and extend researches to bone matrix reconstitution and wound healing. We anticipate with much pleasure that soon patents will be also granted in other countries.”
About Bio3 Research S.r.l.
Bio3 Research S.r.l., an Italian company founded in 2001, has headquarters in Milan and an office at the Bioindustry Park of Canavese (Turin). Bio3 Research works with research institutions, individual scientists and early-stage companies to identify, protect and exploit commercially promising intellectual property in the life sciences. Such assistance may include pre-clinical development and negotiation of strategic industrial partnerships. Bio3 Research’s activity focuses mainly on the field of HMBG1-related cardiovascular disorders and use of HMGB1 and its fragments in connective tissue regeneration. Other fields of interest include skin and renal diseases.
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements
Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!
Distribution: [+] Free Press Release & Newswire Distribution Network. via PRZOOM - Newswire Today (NewswireToday.com)
# # #
Your Banner Ad showing on ALL Pharma/BioTech/Nutrition articles, CATCH Visitors via Your Competitors Announcements! Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
Newswire Today - PRZOOM disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
